Coudert, B., Asselain, B., Campone, M., Spielmann, M., Machiels, J., Pénault-Llorca, F., . . . Roché, H. (2012). Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. AlphaMed Press.
Citação norma ChicagoCoudert, Bruno, et al. Extended Benefit From Sequential Administration of Docetaxel After Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. AlphaMed Press, 2012.
MLA CitationCoudert, Bruno, et al. Extended Benefit From Sequential Administration of Docetaxel After Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. AlphaMed Press, 2012.